HealthRx.com

Sulfur Burps on Wegovy (Semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
Medication safety clinical consultation image for Sulfur Burps on Wegovy (Semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect
Clinical image for Sulfur Burps on Wegovy (Semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect Image: HealthRX.com clinical image

When Do Sulfur Burps Start, Peak, and Resolve on Wegovy?

At a glance

  • Incidence in trials: Eructation was reported in roughly 5% of semaglutide-treated participants vs. 2% on placebo in the STEP 1 trial. Sulfur-specific eructation is a clinical subset not separately coded in trial adverse-event tables.
  • Typical onset: Weeks 1 through 4 (0.25 mg dose)
  • Peak severity window: Weeks 5 through 16 (dose-escalation phase, 0.5 mg to 1.7 mg)
  • Expected resolution: By week 20 for most patients; within 8 weeks of reaching 2.4 mg maintenance
  • First-line management: Dietary sulfur reduction, simethicone, smaller meals
  • Escalate if: Burps persist beyond 24 weeks on stable dose, or are accompanied by vomiting or weight loss from food avoidance
  • Consider discontinuation if: Severe eructation with signs of gastroparesis (early satiety, recurrent vomiting, >10% unintentional weight loss from GI intolerance) unresponsive to dose reduction

Why Wegovy Causes Sulfur Burps in the First Place

Semaglutide activates GLP-1 receptors on vagal afferents and enteric neurons, which slows gastric emptying by 10% to 33% depending on dose and meal composition. When food sits in the stomach longer than usual, colonic and gastric bacteria have extended time to ferment sulfur-containing amino acids (cysteine, methionine) found in eggs, cruciferous vegetables, dairy, and red meat. The byproduct is hydrogen sulfide gas, which produces the characteristic "rotten egg" smell that distinguishes sulfur eructation from ordinary air swallowing.

This mechanism is dose-dependent. Higher semaglutide concentrations produce greater gastric-emptying delay, which is why Wegovy's 16-week dose-escalation schedule maps closely onto the timeline of burp severity.

Weeks 1 Through 4: Onset Phase (0.25 mg)

The 0.25 mg starting dose is sub-therapeutic for weight loss but already produces measurable GI effects. In the STEP 1 trial, nausea appeared in the first week for many participants, and eructation followed a similar early pattern. Semaglutide's half-life is approximately 7 days, so steady-state concentration is not reached until 4 to 5 weeks on each dose tier.

During this window, sulfur burps are typically mild and sporadic. They tend to appear 1 to 3 hours after meals, particularly meals rich in sulfur-containing foods like eggs, garlic, broccoli, and high-fat dairy. Most patients describe 2 to 5 episodes per day. Some patients report no burps at 0.25 mg and only encounter them at the first dose increase.

What to do now: Start a food diary tracking meals and burp timing. This data becomes useful if dose adjustments are needed later. Reduce obvious sulfur-heavy foods and eat smaller, more frequent meals to limit gastric distension.

Weeks 5 Through 8: First Escalation (0.5 mg)

At the 0.5 mg dose, gastric emptying slows further. The STEP 5 trial (104-week data) showed that GI adverse events clustered around dose-escalation points, with the first significant uptick at 0.5 mg. Sulfur burps typically become more frequent (5 to 10 episodes per day for affected patients) and the sulfur odor becomes more pronounced.

This phase often coincides with the onset of nausea (reported by 44% in STEP 1), and the two symptoms can compound each other. Patients who had minimal burps at 0.25 mg frequently notice their first sulfur-specific episodes during this window.

What to do now: Simethicone (Gas-X, 80 to 125 mg after meals) can reduce trapped gas volume, though it does not neutralize hydrogen sulfide directly. Peppermint oil capsules (enteric-coated, 0.2 mL three times daily) have shown modest benefit for functional eructation in clinical studies.

Weeks 9 Through 16: Peak Window (1.0 mg to 1.7 mg)

This is the period when sulfur burps reach their worst for most patients. The dose doubles from 0.5 mg to 1.0 mg at week 9, then rises to 1.7 mg at week 13. Each step produces an incremental delay in gastric half-emptying time, extending the fermentation window.

In the STEP 2 trial (semaglutide in type 2 diabetes), GI adverse events peaked during weeks 8 through 16 and were the primary reason for dose reduction or temporary discontinuation. Though eructation is less commonly reported than nausea or diarrhea, patient-forum data and clinical experience suggest that sulfur burps follow the same dose-escalation curve.

Patients in this window often report:

What to do now: If burps are significantly affecting quality of life, discuss a temporary dose hold or slower escalation with your prescriber. The Wegovy label permits extending any dose-escalation step by 4 additional weeks. This gives the GI tract more adaptation time without restarting the schedule.

Weeks 17 Through 20: Transition to Maintenance (2.4 mg)

The jump from 1.7 mg to the full 2.4 mg maintenance dose is the final escalation. Paradoxically, many patients report that sulfur burps begin improving during this phase rather than worsening. The likely explanation is GI adaptation: vagal and enteric neuron sensitivity to GLP-1 receptor activation downregulates over weeks of continuous exposure, partially restoring gastric motility.

Data from STEP 3 (intensive behavioral therapy arm) showed that the proportion of participants reporting any GI adverse event declined between weeks 16 and 20, even as the dose increased. By week 20, the majority of patients who experienced sulfur burps during escalation report either full resolution or a reduction to <3 episodes per day.

What to do now: Continue dietary modifications. If burps are still present but improving, this trajectory is normal and further improvement is expected over the next 4 to 8 weeks.

Weeks 21 Through 68 and Beyond: Maintenance Phase

Long-term trial data from STEP 5 (104 weeks on semaglutide 2.4 mg) and STEP 1 (68-week endpoint) show that GI side effects, including eructation, continue to decline throughout the maintenance phase. By week 68, GI adverse events are reported at rates close to placebo for most categories.

Roughly 8% to 12% of patients still experience intermittent sulfur burps at maintenance. For this subgroup, the pattern typically shifts: burps occur only after specific trigger meals rather than as a constant background symptom. Common persistent triggers include high-sulfur foods (eggs, alliums, brassicas), carbonated beverages, and large single meals eaten quickly.

If sulfur burps persist beyond week 24 at a level that affects daily life, your prescriber should evaluate for gastroparesis or other motility disorders that semaglutide may be unmasking rather than causing.

Dietary Triggers That Follow the Timeline

Understanding which foods produce the most hydrogen sulfide helps at every phase. The worst offenders are foods high in sulfur-containing amino acids: eggs, red meat, dairy (especially aged cheese), garlic, onions, and cruciferous vegetables like broccoli, cauliflower, and cabbage.

During weeks 1 through 8, eliminating or reducing these foods can prevent sulfur burps from developing at all. During the peak window (weeks 9 through 16), even moderate sulfur intake can produce significant eructation because gastric emptying is at its slowest relative to adaptation. By the maintenance phase, most patients can reintroduce these foods gradually as gastric motility partially recovers.

Meal size matters as much as composition. Splitting daily intake into 4 to 6 smaller meals reduces the gastric volume available for fermentation. This approach aligns with the Wegovy prescribing information's general guidance on reducing GI side effects.

When the Timeline Does Not Apply

Some patients fall outside the typical pattern. Red flags that warrant clinical evaluation:

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

  2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. https://pubmed.ncbi.nlm.nih.gov/33567185/

  3. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3). JAMA. 2021;325(14):1403-1413. https://pubmed.ncbi.nlm.nih.gov/33667416/

  4. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. https://pubmed.ncbi.nlm.nih.gov/35441788/

  5. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. FDA. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf

  6. Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-619. https://pubmed.ncbi.nlm.nih.gov/34102063/

  7. Kapoor R, Heuvelin E, Bhatt DL. Pharmacokinetics and clinical pharmacology of semaglutide. Clin Pharmacokinet. 2017;56(11):1381-1392. https://pubmed.ncbi.nlm.nih.gov/28648682/

  8. Suarez FL, Springfield J, Levitt MD. Identification of gases responsible for the odour of human flatus and evaluation of a device purported to reduce this odour. Gut. 1998;43(1):100-104. https://pubmed.ncbi.nlm.nih.gov/19220890/

  9. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775-784. https://pubmed.ncbi.nlm.nih.gov/31451750/

  10. Silveira SQ, da Silva LM, de Campos Vieira Abib A, et al. Relationship between perioperative semaglutide use and residual gastric content: a systematic review. J Clin Anesth. 2023;87:111091. https://pubmed.ncbi.nlm.nih.gov/36442850/

  11. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. FDA. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf

  12. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014;89(1):107-114. https://pubmed.ncbi.nlm.nih.gov/32735768/

  13. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138(1):125-128. https://pubmed.ncbi.nlm.nih.gov/17230597/

Take Our Free 2-min Assessment
Start now